Add To Watchlist
Share URL
About The Company
Description
Abliva AB (publ) develops medicines for the treatment of primary mitochondrial diseases.
Read More
Overview
Value
7
Growth
64
Health
17
Management
57
Analyst Opinion
60
Total
41
All Scores Out Of 100
Best Features
- Very strong cashflow and earnings growth
- Earnings growth has improved recently
- Has a low level of debt
- Low preportion of income is paid as dividend
Risk Factors
- Overvalued on cashflow basis
- Income is not covering expenditure and investment
- Earnings are negative
- There is a history of diluting shareholders
- Poor overall financial health
- No margin of safety at their current market price
- Accounting anomalies: Growing revenues without a corresponding growth in cash flows. 0
Market Peers
ABLI.ST
Key Figures
PE Ratio (TTM)
N/A
Margin Of Safety (DCF)
-49.75%
Revenue Growth (5 Year Average)
29.52%
Ratings Consensus
Neutral
Share Buybacks
-62.18%
Dividend Yeild (TTM)
N/A
Valuation
Value Score
7
Desired Margin Of Safety
0%
▼
Tip: Set your desired Margin Of Safety
Free Cash Flow Type
Annual Cashflow Growth
0%
Discount Rate
0%
Buy Target: N/A✘
Current Price: 0.3 SEK
Negative Cashflows: Cashflow can become negative due to operating losses, investing activities or financing activites. Negative cashflow makes it dificult to use a discounted free cashflow model to assess intrinsic value.
How Does This Work?
Show Advanced Options
This calculator helps investors estimate the Intrinsic Value of a company based on the current value of future cash flows. To use the tool, simply input a desired Margin Of Safety, which is an additional discount applied to the present value of the expected future cash flows. The tool calculates the present value using a discount rate that reflects the risk and time value of money, and provides an estimated target price for the company based on the selected margin of safety. The calculator defaults to using 5 Year Free Cash Flow Growth % and a discount rate based on the US 10-year treasury bond coupon rate. Use our performance analyser to get a feel the impact this has on longterm investment returns and discover a margin of safety you are comfortable with. This can be a useful tool for investors looking to make informed decisions about whether to buy or sell shares of a particular company.
Price/Earnings
N/Ax
Free Cashflow Yeild
-73.66%
PE/Earnings Growth
N/A
Price/Book
1.45x
Growth
Growth Score
64
- ✔ 5 Year Average Revenue growth of 29.52% is higher than the market average (10.97%)
- ✔ 5 Year Average Earnings growth of 20.96% is higher than the market average (14.48%)
- ✔ Earnings growth has improved this year
- ✘ Revenue growth has slowed this year
- ✘ 5 Year Average Free Cashflow growth of -1.38% is lower than the market average (12.35%)
- ✘ Free Cashflow growth has slowed this year
Revenue Growth
29.52%
Earnings Growth
20.96%
Cashflow Growth
-1.38%
Health
Health Score
17
Altman Z Score
0.86
Piostroski Score
1.00
Debt/Equity
N/Ax
Current Assets/Liabilities
1.39x
Free Cashflow/Total Debt
N/Ax
Debt/Capital
N/Ax
Management
Management Score
57
Average Buybacks/Dilution
-62.18%
Recent Buybacks/Dilution
N/A
5 Year Price Volitility
67.65%
Return On Assets
-591.63%
Return On Capital Employed
-154.84%
Return On Equity
-839.57%
Return On Free Cashflow
505.44%
Return On Investments
-2660.71%
Analysts
Analyst Opinion
60
- ✔ Ratings consensus is Neutral
SEC Filings
Find yearly (10-K), quaterly (10-Q) and disclosure (8-K) report here, on the Securities and Exchange Commission's EDGAR database. If reading through reports isn't your cup of tea, don't worry. We've made it easy for you by summarizing all the important bits.
Other Information
Company Name
Abliva AB (publ)
Currency
SEK
Beta
0.809411
Vol Avg
11695298
Ceo
Dr. Ellen K. Donnelly Ph.D.
Cik
Cusip
Exchange
Stockholm Stock Exchange
Full Time Employees
8
Industry
Biotechnology
Sector
Healthcare
Ipo Date
2008-10-03
Address
Medicon Village
City
Lund
State
Country
SE
Zip
223 81
Phone
46 4 62 75 62 20
All financial data provided by FMP